Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASXC Asensus Surgical	$0.35	$0.35	$0.17 ▼ $0.40	$94.74M	1.37	2.03 million shs	N/A
BFLY Butterfly Network	$1.39 +1.8%	$1.94	$0.90 ▼ $4.98	$342.37M	2.45	3.87 million shs	2.52 million shs
DCTH Delcath Systems	$10.88 +3.5%	$12.74	$7.17 ▼ $18.23	$367.65M	0.82	887,317 shs	776,894 shs
TMCI Treace Medical Concepts	$6.53 +2.2%	$5.83	$4.54 ▼ $10.79	$403.68M	0.68	316,289 shs	558,765 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASXC Asensus Surgical	0.00%	0.00%	0.00%	0.00%	+3.67%
BFLY Butterfly Network	+2.25%	-4.21%	-24.59%	-42.65%	+41.39%
DCTH Delcath Systems	+5.00%	-6.74%	-7.32%	-31.26%	+35.09%
TMCI Treace Medical Concepts	+4.24%	+13.90%	+6.50%	-8.45%	+10.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BFLY Butterfly Network	2.2168 of 5 stars	3.4	1.0	0.0	0.0	2.3	2.5	0.6
DCTH Delcath Systems	2.8494 of 5 stars	3.5	2.0	0.0	0.0	3.0	2.5	0.6
TMCI Treace Medical Concepts	2.294 of 5 stars	3.2	1.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASXC Asensus Surgical	0.00	N/A	N/A	N/A
BFLY Butterfly Network	2.75	Moderate Buy	$3.00	116.61% Upside
DCTH Delcath Systems	3.00	Buy	$24.50	125.18% Upside
TMCI Treace Medical Concepts	2.33	Hold	$9.83	50.59% Upside

Current Analyst Ratings Breakdown

Latest ASXC, DCTH, TMCI, and BFLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$8.60 ➝ $6.50
8/8/2025	TMCI Treace Medical Concepts	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $6.00
8/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00
8/4/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$2.00
8/1/2025	BFLY Butterfly Network	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/1/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
6/23/2025	DCTH Delcath Systems	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASXC Asensus Surgical	$8.58M	11.04	N/A	N/A	$0.13 per share	2.68
BFLY Butterfly Network	$82.06M	4.25	N/A	N/A	$0.92 per share	1.51
DCTH Delcath Systems	$37.21M	10.23	N/A	N/A	$3.00 per share	3.63
TMCI Treace Medical Concepts	$209.36M	1.97	N/A	N/A	$1.55 per share	4.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASXC Asensus Surgical	-$78.43M	-$0.31	N/A	N/A	N/A	-902.25%	-184.10%	-114.75%	N/A
BFLY Butterfly Network	-$72.49M	-$0.28	N/A	N/A	N/A	-71.79%	-30.53%	-21.80%	N/A
DCTH Delcath Systems	-$26.39M	$0.05	217.60	N/A	N/A	3.18%	6.91%	5.80%	N/A
TMCI Treace Medical Concepts	-$55.74M	-$0.79	N/A	N/A	N/A	-23.01%	-46.76%	-23.35%	N/A

Latest ASXC, DCTH, TMCI, and BFLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	TMCI Treace Medical Concepts	-$0.29	-$0.28	+$0.01	-$0.28	$47.08 million	$47.39 million
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	$0.07	+$0.05	$0.07	$22.84 million	$24.16 million
8/1/2025	Q2 2025	BFLY Butterfly Network	-$0.07	-$0.06	+$0.01	-$0.06	$23.91 million	$23.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASXC Asensus Surgical	N/A	N/A	N/A	N/A	N/A
BFLY Butterfly Network	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASXC Asensus Surgical	N/A	1.00	0.69
BFLY Butterfly Network	N/A	5.68	4.14
DCTH Delcath Systems	N/A	10.88	9.87
TMCI Treace Medical Concepts	0.51	4.50	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASXC Asensus Surgical	9.35%
BFLY Butterfly Network	37.85%
DCTH Delcath Systems	61.12%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
ASXC Asensus Surgical	2.87%
BFLY Butterfly Network	25.18%
DCTH Delcath Systems	17.94%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASXC Asensus Surgical	170	272.33 million	264.52 million	Not Optionable
BFLY Butterfly Network	460	251.74 million	188.35 million	Optionable
DCTH Delcath Systems	60	34.98 million	28.71 million	Optionable
TMCI Treace Medical Concepts	250	63.17 million	45.66 million	Optionable

ASXC, DCTH, TMCI, and BFLY Headlines

Recent News About These Companies

Treace Medical Concepts: Positive Q2 Earnings Call Highlights

1 hour ago | tipranks.com

Analysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest Report

August 12 at 3:16 AM | finance.yahoo.com

Treace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Expectations By $0.01 EPS

August 11 at 2:33 PM | marketbeat.com

UBS Group Cuts Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.50

August 10 at 3:09 PM | marketbeat.com

Arcadia Wealth Management Inc. Invests $1.76 Million in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 10 at 6:37 AM | marketbeat.com

Stifel Nicolaus Lowers Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.00

August 10 at 3:31 AM | americanbankingnews.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2025 Earnings Call Transcript

August 9 at 6:31 PM | msn.com

Stifel Nicolaus Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock Price

August 9 at 12:47 PM | marketbeat.com

Treace Medical Concepts Inc (TMCI) Q2 2025 Earnings Call Highlights: Revenue Growth and ...

August 8, 2025 | uk.finance.yahoo.com

Treace Medical anticipates 7–10% revenue growth in 2025 while launching next-gen bunion solutions

August 8, 2025 | msn.com

Treace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Treace Medical (TMCI) Q2 Revenue Up 7%

August 7, 2025 | fool.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Treace Medical Concepts ReportsÂ Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025

August 7, 2025 | globenewswire.com

Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study

August 5, 2025 | finance.yahoo.com

Treace Medical Concepts (TMCI) Projected to Post Quarterly Earnings on Thursday

August 5, 2025 | americanbankingnews.com

GSA Capital Partners LLP Buys Shares of 66,790 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 4, 2025 | marketbeat.com

Analysts Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $10.52

August 4, 2025 | americanbankingnews.com

Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

Legato Capital Management LLC Purchases Shares of 56,220 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

July 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASXC, DCTH, TMCI, and BFLY Company Descriptions

Asensus Surgical NYSEAMERICAN:ASXC

$0.35 0.00 (0.00%)

As of 08/22/2024

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

Butterfly Network NYSE:BFLY

$1.38 +0.03 (+1.84%)

Closing price 03:59 PM Eastern

Extended Trading

$1.42 +0.03 (+2.53%)

As of 08:00 PM Eastern

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Delcath Systems NASDAQ:DCTH

$10.88 +0.37 (+3.52%)

Closing price 04:00 PM Eastern

Extended Trading

$10.84 -0.04 (-0.41%)

As of 06:59 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Treace Medical Concepts NASDAQ:TMCI

$6.53 +0.14 (+2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$6.54 +0.00 (+0.08%)

As of 04:10 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time